Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Spero grants new employee 217,000 restricted stock units under Nasdaq Rule 5635(c)(4)
- ➤Spero grants new employee 434,000 stock options under its inducement equity plan
- ➤Stock options vest 25% after one year, then monthly over 36 months
- ➤Restricted stock units vest in four equal annual installments
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that the Compensation Committee of Spero’s Board of Directors approved a grant, made on November 2, 2026, of an aggregate of 217,000 restricted stock unit awards (RSUs) and 434,000 stock options to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employee in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as a material inducement for such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
Get started
Create a free account to read the full story.